Ironwood Pharmaceuti (IRWD) 13.35 $IRWD Ironwoo
Post# of 273331
Posted On: 09/02/2016 1:06:48 AM
Ironwood Pharmaceuti (IRWD) 13.35 $IRWD
Ironwood Pharmaceuticals to Present at Wells Fargo 2016 Healthcare Conference
BusinessWire - Thu Sep 01, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Wells Fargo 2016 Healthcare Conference on Wednesday, September 7, 2016 at 2:20 p.m. Eastern Time at the Westin Waterfront Hotel in Boston.
IRWD: 13.35 (+0.01), WFC: 50.43 (-0.37)
Research Report Initiation on Generic Drugs Makers Stocks -- Ironwood Pharma, The Medicines, Carbylan Therapeutics, and Pacira Pharma
PR Newswire - Wed Aug 24, 7:00AM CDT
The global Generic Drugs market is forecasted to grow at a CAGR of 10.53% over the period of 2016 to 2020, according to the 'Global Generic Drugs Market 2016-2020' report released in June 2016. Today, Stock-Callers.com assesses the following companies stocks to see if they are poised for higher returns: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), The Medicines Co. (NASDAQ: MDCO), Carbylan Therapeutics Inc. (NASDAQ: CBYL), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
IRWD: 13.35 (+0.01), MDCO: 38.97 (-0.20), CBYL: 0.48 (+0.01), PCRX: 40.37 (+0.74)
Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
BusinessWire - Thu Aug 04, 3:05PM CDT
--- LINZESS(R) (linaclotide) U.S. net sales increased 34% to $150.5 million in 2Q 2016 over 2Q 2015; net profit for the brand increased to $58 million from $15 million -
IRWD: 13.35 (+0.01)
Catalyst (CPRX) Q2 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 5:11PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX ) is scheduled to report second-quarter 2016 results on Aug 9.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), CPRX: 0.96 (-0.05), MYL: 41.92 (-0.44)
Why Ironwood Pharmaceuticals (IRWD) Might Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:59AM CDT
Ironwood Pharmaceuticals (IRWD) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory
IRWD: 13.35 (+0.01)
What's in Store for Merck KGaA (MKGAF) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:06AM CDT
Merck KGaA (MKGAF) is scheduled to report second-quarter 2016 earnings results on Aug 4.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), PFE: 34.68 (-0.12)
What Awaits Radius Health (RDUS) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:02AM CDT
Radius Health (RDUS) is scheduled to report second-quarter 2016 results on Aug 4.
IPXL: 23.94 (-0.25), RDUS: 55.68 (+0.84), IRWD: 13.35 (+0.01), NVS: 78.27 (-0.50)
Intercept (ICPT) Likely to Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:26AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report second-quarter 2016 results on Aug 4, after the market closes.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), ICPT: 146.82 (-1.49), MYL: 41.92 (-0.44)
What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report second-quarter 2016 results after the market closes on Aug 3.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), AERI: 19.21 (-0.15), EXEL: 11.35 (+0.20)
Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Merrimack (MACK) is scheduled to report second-quarter 2016 results on Aug 4.
MACK: 4.59 (-0.03), IRWD: 13.35 (+0.01), LLY: 77.23 (-0.52), EXEL: 11.35 (+0.20)
Exelixis (EXEL) Q2 Earnings Preview: Stock Likely to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:55AM CDT
Exelixis, Inc. (EXEL) is scheduled to report second-quarter 2016 results on Aug 3 after the market closes.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), EXEL: 11.35 (+0.20)
Aegerion (AEGR): What Awaits for the Stock in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:03AM CDT
Aegerion (AEGR) is expected to report second-quarter 2016 results on Aug 3.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), AEGR: 1.59 (-0.04), EXEL: 11.35 (+0.20)
Keryx (KERX) Q2 Earnings Preview: Will the Stock Gain?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 4:13PM CDT
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report second-quarter 2016 results on Aug 3.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), KERX: 4.13 (+0.03), EXEL: 11.35 (+0.20)
What's in Store for Prothena (PRTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:44PM CDT
Prothena Corporation plc (PRTA) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), PRTA: 52.21 (+2.23), EXEL: 11.35 (+0.20)
Whta's in Store for Endocyte (ECYT) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Endocyte, Inc. (ECYT) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 23.94 (-0.25), ECYT: 2.95 (-0.03), IRWD: 13.35 (+0.01), EXEL: 11.35 (+0.20)
Mallinckrodt (MNK) Q3 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:47PM CDT
Mallinckrodt plc (MNK) is set to report third-quarter fiscal 2016 results on Aug 2.
MNK: 75.59 (+1.05), IRWD: 13.35 (+0.01), MDCO: 38.97 (-0.20), EXEL: 11.35 (+0.20)
AmerisourceBergen (ABC) Q3 Earnings: Stock to Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 11:10AM CDT
AmerisourceBergen Corporation (ABC) is set to report third-quarter fiscal 2016 results on Aug 2, before the opening bell.
ABC: 87.15 (+0.18), WBA: 81.54 (+0.83), IRWD: 13.35 (+0.01), BMY: 56.76 (-0.63)
First Week of February 2017 Options Trading For Ironwood Pharmaceuticals (IRWD)
DividendChannel.com - Tue Jun 21, 10:00AM CDT
Investors in Ironwood Pharmaceuticals Inc. saw new options begin trading this week, for the February 2017 expiration.
IRWD: 13.35 (+0.01)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 237.76 (+3.22), IRWD: 13.35 (+0.01), AZN: 32.60 (-0.21), JNP: 5.51 (-0.01)
Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.35 (+0.01), CPRX: 0.96 (-0.05), AKRX: 26.68 (-0.24), PCRX: 40.37 (+0.74)
Ironwood Pharmaceuticals to Present at Wells Fargo 2016 Healthcare Conference
BusinessWire - Thu Sep 01, 3:01PM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Wells Fargo 2016 Healthcare Conference on Wednesday, September 7, 2016 at 2:20 p.m. Eastern Time at the Westin Waterfront Hotel in Boston.
IRWD: 13.35 (+0.01), WFC: 50.43 (-0.37)
Research Report Initiation on Generic Drugs Makers Stocks -- Ironwood Pharma, The Medicines, Carbylan Therapeutics, and Pacira Pharma
PR Newswire - Wed Aug 24, 7:00AM CDT
The global Generic Drugs market is forecasted to grow at a CAGR of 10.53% over the period of 2016 to 2020, according to the 'Global Generic Drugs Market 2016-2020' report released in June 2016. Today, Stock-Callers.com assesses the following companies stocks to see if they are poised for higher returns: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), The Medicines Co. (NASDAQ: MDCO), Carbylan Therapeutics Inc. (NASDAQ: CBYL), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
IRWD: 13.35 (+0.01), MDCO: 38.97 (-0.20), CBYL: 0.48 (+0.01), PCRX: 40.37 (+0.74)
Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
BusinessWire - Thu Aug 04, 3:05PM CDT
--- LINZESS(R) (linaclotide) U.S. net sales increased 34% to $150.5 million in 2Q 2016 over 2Q 2015; net profit for the brand increased to $58 million from $15 million -
IRWD: 13.35 (+0.01)
Catalyst (CPRX) Q2 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 5:11PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX ) is scheduled to report second-quarter 2016 results on Aug 9.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), CPRX: 0.96 (-0.05), MYL: 41.92 (-0.44)
Why Ironwood Pharmaceuticals (IRWD) Might Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:59AM CDT
Ironwood Pharmaceuticals (IRWD) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory
IRWD: 13.35 (+0.01)
What's in Store for Merck KGaA (MKGAF) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:06AM CDT
Merck KGaA (MKGAF) is scheduled to report second-quarter 2016 earnings results on Aug 4.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), PFE: 34.68 (-0.12)
What Awaits Radius Health (RDUS) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:02AM CDT
Radius Health (RDUS) is scheduled to report second-quarter 2016 results on Aug 4.
IPXL: 23.94 (-0.25), RDUS: 55.68 (+0.84), IRWD: 13.35 (+0.01), NVS: 78.27 (-0.50)
Intercept (ICPT) Likely to Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:26AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report second-quarter 2016 results on Aug 4, after the market closes.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), ICPT: 146.82 (-1.49), MYL: 41.92 (-0.44)
What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report second-quarter 2016 results after the market closes on Aug 3.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), AERI: 19.21 (-0.15), EXEL: 11.35 (+0.20)
Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Merrimack (MACK) is scheduled to report second-quarter 2016 results on Aug 4.
MACK: 4.59 (-0.03), IRWD: 13.35 (+0.01), LLY: 77.23 (-0.52), EXEL: 11.35 (+0.20)
Exelixis (EXEL) Q2 Earnings Preview: Stock Likely to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:55AM CDT
Exelixis, Inc. (EXEL) is scheduled to report second-quarter 2016 results on Aug 3 after the market closes.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), EXEL: 11.35 (+0.20)
Aegerion (AEGR): What Awaits for the Stock in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:03AM CDT
Aegerion (AEGR) is expected to report second-quarter 2016 results on Aug 3.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), AEGR: 1.59 (-0.04), EXEL: 11.35 (+0.20)
Keryx (KERX) Q2 Earnings Preview: Will the Stock Gain?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 4:13PM CDT
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report second-quarter 2016 results on Aug 3.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), KERX: 4.13 (+0.03), EXEL: 11.35 (+0.20)
What's in Store for Prothena (PRTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:44PM CDT
Prothena Corporation plc (PRTA) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 23.94 (-0.25), IRWD: 13.35 (+0.01), PRTA: 52.21 (+2.23), EXEL: 11.35 (+0.20)
Whta's in Store for Endocyte (ECYT) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Endocyte, Inc. (ECYT) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 23.94 (-0.25), ECYT: 2.95 (-0.03), IRWD: 13.35 (+0.01), EXEL: 11.35 (+0.20)
Mallinckrodt (MNK) Q3 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:47PM CDT
Mallinckrodt plc (MNK) is set to report third-quarter fiscal 2016 results on Aug 2.
MNK: 75.59 (+1.05), IRWD: 13.35 (+0.01), MDCO: 38.97 (-0.20), EXEL: 11.35 (+0.20)
AmerisourceBergen (ABC) Q3 Earnings: Stock to Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 11:10AM CDT
AmerisourceBergen Corporation (ABC) is set to report third-quarter fiscal 2016 results on Aug 2, before the opening bell.
ABC: 87.15 (+0.18), WBA: 81.54 (+0.83), IRWD: 13.35 (+0.01), BMY: 56.76 (-0.63)
First Week of February 2017 Options Trading For Ironwood Pharmaceuticals (IRWD)
DividendChannel.com - Tue Jun 21, 10:00AM CDT
Investors in Ironwood Pharmaceuticals Inc. saw new options begin trading this week, for the February 2017 expiration.
IRWD: 13.35 (+0.01)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 237.76 (+3.22), IRWD: 13.35 (+0.01), AZN: 32.60 (-0.21), JNP: 5.51 (-0.01)
Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.35 (+0.01), CPRX: 0.96 (-0.05), AKRX: 26.68 (-0.24), PCRX: 40.37 (+0.74)
(0)
(0)